我国7月1日起全面实施医保药品扫码结算

Group 1 - The National Healthcare Security Administration (NHSA) has made significant progress in addressing issues related to the management of medical insurance funds, particularly in combating illegal activities such as the resale of "returned drugs" [1] - "Returned drugs" refer to pharmaceuticals that have exited the legitimate distribution channels and re-entered the market, often through illegal means, posing risks to public health and safety [1] - The NHSA has launched a drug traceability information query function on its platform, allowing pharmacies to identify "returned drugs" through scanning, thereby ensuring the legality of drug sources [1][2] Group 2 - As of now, the NHSA has collected a total of 39.885 billion drug traceability codes to assist in combating the "returned drug" issue [2] - The NHSA plans to enhance the regulatory application of drug traceability codes, focusing on building a big data regulatory model to combat illegal drug trading and other violations [2] - The NHSA has initiated a special action to combat the production and sale of counterfeit and inferior drugs, with the first phase of verification tasks completed and several cases of "returned drugs" being addressed [2]